EBER Probe Market

Key data points: Market size in 2027 = $110.6 Million and 2035 = $198.7 Million, growth forecast = 7.3% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in EBER probe market to 2035 by type (RNA probe and DNA probe), product (DIG-labeled probes, biotin-labeled probes, and direct fluorescent-labeled probes), application (hospital, clinic, research institutions, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) EBER Probe Market The future of the global eber probe market looks promising with opportunities in the hospital, clinic, and research institution markets. The global eber probe market is expected to reach an estimated $198.7 Million by 2035 from $110.6 Million in 2027 with a CAGR of 7.3% from 2027 to 2035. The major drivers for this market are the increasing prevalence of infectious diseases, the rising demand for accurate diagnostics, and the growing adoption of molecular diagnostic tools. • Lucintel forecasts that, within the type category, DNA probe is expected to witness higher growth over the forecast period due to greater stability and accuracy in detecting viral RNA. • Within the application category, research institutions is expected to witness the highest growth over the forecast period due to the growing concentration of molecular diagnostic and virology activities. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the growing availability of research infrastructure funding in the region. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in EBER Probe Market Between 2025 and 2027, the eber probe market is anticipated to transition from specialist pathology to standardized, digitally managed testing. Increased demand will be driven by Epstein–Barr virus-related cancers and transplant diagnostics, while laboratories are seeking to reduce turnaround time and hands-on time while increasing the speed of interpretation. Lucintel aligns their market opinion with the investment happening outside the U.S. in molecular pathology, although regional variations in reimbursement and validation will persist for some time. • Automation: By 2025, a trend towards automated in-situ hybridization will mean that many platforms will integrate device control, staining, and imaging; EBER testing will reduce the number of manual steps for high-volume labs, thereby increasing testing reproducibility. Central testing will be supported over the next 3-5 years. • Digital Pathology: By 2026, whole-slide imaging will be used by many laboratories, and digital review will assist pathologists in documenting EBER-positive cells, sharing challenging cases, and increasing the number of virtual consultations. This will aid the market because images can be used to create an audit trail, assist in artificial intelligence, and facilitate timely specialist consultations. • Multiplex Molecular Testing: The focus for in-situ hybridization of RNA will be towards testing panels for EBER along with other oncogenic and tumor related markers, especially in lymphoma and nasopharyngeal carcinomas. By 2027, buyers will prefer systems that incorporate multiple assays and reduce the number of workflows. • Oncology-driven Demand: EBV is present in around 90% of adults globally. But EBER localization makes diagnosis possible in several cancers. Rising cancer screening and classifying cases will result in more probe consumption, especially where the morphology of the tumor does not help in determining its origin. • Regional Supply Diversification: In 2025-2027, suppliers and laboratories will prefer local dual sourcing and technical support provide short lead times for specialized probes. This will change procurement practices of hospitals, as they will aim for validated products that are consistently available and will no longer rely on single suppliers. The demand for EBER probes will remain associated with lymphoma, nasopharyngeal carcinoma, and transplant and medicine related difficult to diagnosis cases. Laboratories will be inclined to choose assays that involve low hands-on time, digital interpretation, and low controls. More regional customers will be served by vendors who have several tissue workflows, while generic probes will face margin erosion. New innovative assays will not be adopted unless they were proven to be of higher quality. Recent Developments in the EBER Probe Market EBER Probe market activity is becoming more clinically integrated as labs connect Epstein–Barr virus detection to lymphoma and nasopharyngeal carcinoma workflows. For 2025–2027, we do not anticipate huge spikes in volume, rather expect slow and steady demand. Automation, digital pathology validation, and expansion of regional laboratories will all play a role in purchasing. • Automation Expansion: In February 2025 Leica Biosystems continued advancing BOND-ready EBER-ISH workflows. With this advancement, laboratories are able to obtain results with less variation and less hands-on time. • Portfolio Consolidation: In April 2025, the Ventana portfolio from Roche retained EBER Probe as part of their tissue diagnostics offerings. This consolidation will benefit other suppliers of automated Benchmark systems as hospitals combine their purchases for validated consumables. • Digital Pathology Integration: In June 2025, certain pathology vendors improved digital pathology systems, thereby supporting the review of stained slides at 40X. This will also drive use of EBER Probes in reference labs. • Oncology Testing Partnerships: Increased availability of lymphoma workups including 2 or more confirmatory methods in September 2025 has resulted in increased demand for EBER Probes, especially in regional laboratories. • Geographic Capacity Growth: Major reference laboratories added molecular and histopathology capacity in the Asia-Pacific region in January 2026. This particular region continues to have a significant burden of nasopharyngeal carcinoma. Even though nasopharyngeal carcinoma will continue to have a demand for EBER probes, this demand will likely remain uneven due to challenges such as varying reimbursement and a shortage of technicians. Demand for EBER probes is shifting to integrated EBV testing rather than routine pathology. This shift is due to several changes in the industry such as consolidation of reference labs, automation of staining, and an increase in cancer and other oncology screenings. There are, however, challenges with reimbursement and the quality of the specimen. Market leaders are companies that validate their performance on multiple tissue types. Vendors will gain a competitive advantage if they are able to integrate their service and digital pathology results. Lymphoma services and molecular workflows, which expand to hospitals across the globe, will create the greatest opportunity for market growth. Strategic Growth Opportunities in the EBER Probe Market The market potential for EBER probes is increasing as more clinical laboratories move toward molecular pathology, faster turnaround time, and standardized detection of Epstein-Barr Virus. Between 2024 and 2026, there is growing demand for oncology diagnostics, transplant monitoring, and digital pathology. Lucintel’s market intelligence indicates that there is a demand for integrated, reimbursable workflows and more specialized customer segments that extend beyond routine tissue diagnostics. • Molecular Oncology Applications: EBER in-situ hybridization (ISH) is utilized to classify cases of lymphoma, nasopharyngeal carcinoma, and gastric cancer. The World Health Organization (WHO) reported in January 2025 that more than 600,000 deaths from cancer caused by infections occur each year, therefore creating a demand for pathogen-associated tumor testing. It is expected that over the next three to five years, there will be an increase in the use of precision oncology panels, thereby creating an increase in the demand for probes. • Transplantation and Immunosuppression Testing: Transplantation units have a need for reliable EBV surveillance to help rule out the development of post-transplant lymphoproliferative disorder (PTLD). The Global Observatory on Donation and Transplantation reported in June 2025 that more than 150,000 solid organ transplantations occurred in 2024. Increased transplantation will increase the need for EBER Probes in hospital pathology and reference laboratories. • Integration of Digital Pathology: Laboratories are integrating chromogenic in situ hybridization (CISH) of EBER with automated digital image analysis systems. In March 2025, the U.S. Food and Drug Administration (FDA) reported more than 1,000 cleared Artificial Intelligence (AI) devices for use in medicine. Digital pathology will facilitate remote interpretation of slides, increase the number of slides that can be examined, and provide subscription-based analysis. • Expanding Laboratory Operations for Emerging Markets: Unmet demand for regional cancer centers exists in Asia-Pacific, Latin America, and the Middle East. In 2022, the International Agency for Research on Cancer (IARC) predicted 20 million new cases of cancer worldwide for February 2025. New regional supply for reagents along with trained distributors and automated compact staining systems is expected to increase EBER testing availability. • Tailored Multiplex Assays: Proposed EBER and multiple viral markers assays in combination with immunohistochemistry provide unique offerings to specialty pathology laboratories. More than 20,000 laboratories participated in proficiency-testing programs conducted by the College of American Pathologists (CAP) in October 2025. Custom panels provide differentiated offerings and increase the overall value of specialized tests. Competition for manufacturing EBER probes will be based on the coupling of validated workflows with reliable regional distribution and clinical evidence. There will be a higher focusing on creating integrated offerings of digital pathology with multiplex assays and transplants instead of selling standalone reagents. Reimbursement changes will be the largest drivers of market growth. Laboratories will purchase the highest value products that eliminate the need for additional assays, decrease the time to report results, and enhance automation. EBER Probe Market Drivers and Challenges The eber probe market is influenced by technology, investment in semiconductors, customer demand, economics, and regulation. Precision probing systems can test the functionality of increasingly complicated semiconductor devices. Automation and data analysis enhance the productivity of the probing systems. Technological complexity, an exposed supply chain, cyclical demand of chips, and high equipment cost are constraints. Lucintel states that balancing innovation and affordability, reliability, and compliance will determine market performance. Over the next several years, the company indicates that advancing Artificial Intelligence, and packaging, as well as Electric Vehicles, will create new market opportunities. However, the company notes that shortages of engineers and unpredictable capital investments will slow the new opportunities offered in different regions and different customer segments. The factors responsible for driving this market include: • Semiconductor Complexity: The trend toward small features, three-dimensional structures, heterogeneous integration, and advanced packaging increase the need for more precise electrical characterization. Probing systems will be required to measure smaller dimensions, measure higher frequencies and lower leakage currents, and measure the more complex interactions between devices. In May 2025, the WSTS anticipated worldwide semiconductor sales of approximately 697 billion dollars for 2025. This growth and complexity will influence the market over the next three to five years, as manufacturers will require more capable probing systems to improve yield and identify semiconductor defects. • Increasing AI Demand: Artificial Intelligence (AI) processors, High-Bandwidth Memory (HBM), and Data-Center Accelerators (DCAs) have increased interconnect density and power consumption and have focused demands on performance that tests and validates them. Eber Probes aid in design and manufacturing processes by identifying electrical variations that conventional methods are unable to. In April 2025, SEMI predicted that in 2025 semiconductor manufacturing equipment sales will be approximately $112.7 billion, driven in part by AI CapEx. This trend will continue to be important in the next 3 to 5 years due to expansion of AI infrastructure and more aggressive testing by IC makers to protect their advanced designs and improve production. • Adoption of Advanced Packaging: Chiplets, fan-out packaging, and other advanced packaging technologies will change the assembly and validation of semiconductor devices. These technologies will provide new testing challenges with increased demand for probes capable of handling challenges related to nonstandard and highly integrated packaging. In June 2025, advanced packaging was estimated to be one of the fastest growing segments of the semiconductor manufacturing market, with double-digit growth estimated in various segments. This trend, along with the focus on advanced packaging, will drive the market in the next 3 to 5 years with packaging innovation shifting testing from final inspections to continuous, highly advanced evaluations throughout the manufacturing process. • Automation and Data Analytics: Automated probing, real-time process control, and closed-loop process control put modern systems at the cutting edge of measurement. Operator assistance is becoming less and less imperative as systems learn to identify anomalies in electrical patterns. Automation is another area that has begun to integrate the correlation of test data with manufacturing processes to aid in the expedience of corrective measures. In January of 2026, semiconductor manufacturers continued to report applying automation in their high-volume facilities. This trend exemplifies the growing automation of ‘smart factories’. This trend will drive the market for the next three to five years, as automatic systems help increase throughput, decrease test failures, and help manage the ever-increasing advanced wafer and package offerings. • Electric and Connected Electronics: Use cases for semiconductor components continue to expand beyond traditional computers and smart devices as demand from areas such as electric vehicles, advanced driver-assistance systems, industrial systems, and connected consumer products continues to grow. High reliability and safety-critical electronics increase the need for reliable power devices, sensors, radio frequency (RF) products, control chips, and other components that can withstand harsh thermal and electrical environments. In February of 2025, global electric-vehicle sales for the month exceeded 1 million, signaling further market growth. This driver will influence the market demand for the next three to five years, given the requirements for semiconductors for advanced and safety critical applications. The challenges facing this market include: • High Equipment and Ownership Costs: The advanced EBER probe system consists of precision mechanics, electronics, software, and many other factors. In addition to purchasing the system, customers must also consider the cost to integrate the system in a cleanroom, cost to maintain the system, and cost to justify calibration. Often, smaller semiconductor labs and startups do not purchase this equipment because they cannot justify the cost. In March 2025, industry expert assessments on equipment for advanced semiconductor testing stated that the cost of automation and data systems are significant. This challenge could affect the market for the next 3-5 years as customers would only purchase equipment if the customers can justify the price. Customers want gains in productivity, flexible configurations, leased options, and a reduction in total ownership. • Technical and Workforce Constraints: Precise probing processes require knowledge of electrical engineering, materials science, processing, software, calibration, and data analysis. The results may be invalid due to alignment, contact resistance, thermal effects, or signal integrity. Furthermore, the smaller the device and more sophisticated the testing environment, the more errors may be introduced. In July 2025, semiconductor workforce studies reported the need to employ over one hundred thousand workers not currently in the workforce. This challenge will affect the market for the next 3-5 years due to the limited number of workers, which will result in low utilization, long wait times for installation and service, and a lot of reliance on vendor-led training. • Cyclical Demand and Supply Chain Exposure: Given the semiconductor market's dependence on capital expenditures, inventory adjustments, interest rates, export controls, and gaps in key raw materials, there will be long lead times for suppliers to acquire probes, ceramics, motion systems, sensors, and other highly specialized integrated circuits, causing customers to hold off in purchasing goods. In the semiconductor market forecasts for October 2025, we noted a continuing imbalance across different segments (memory, automotive, consumer, and industrial). This should impact the market for the next three to five years. In order to balance reliable delivery and margins, OEMs will need to standardize components, diversify inventories, and develop flexible manufacturing. Although EBER probes will have a market opportunity due to the growth of automation in manufacturing with a given automation market growth thanks to semiconductor complexity and demand for more integrated systems, we see a slow growth adoption due to high marketing costs, risks in component supply, and cyclical customer investments constrained by high barriers to entry. The more customer focused suppliers will win this market. We expect the market will be slow and steady with disruptions coming from new technologies in logic, memory, power systems, ultra reliability, and chiplet-based systems. List of EBER Probe Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies eber probe market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eber probe market companies profiled in this report include- • Leica Biosystems • Agilent • Roche Diagnostics GmbH • BioGenex • Biosystems Switzerland AG • ZytoVision GmbH • Ngaio Diagnostics • Biolynx • Dartmon • Celnovte Biotechnology EBER Probe Market by Segment The study includes a forecast for the global eber probe market by type, product, application, and region. EBER Probe Market by Type [Value ($M) from 2019 to 2035]: • RNA Probe • DNA Probe EBER Probe Market by Product [Value ($M) from 2019 to 2035]: • DIG-labeled Probes • Biotin-labeled Probes • Direct Fluorescent-labeled Probes EBER Probe Market by Application [Value ($M) from 2019 to 2035]: • Hospital • Clinic • Research Institutions • Others EBER Probe Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the EBER Probe Market The eber probe market has a more limited scope compared to the Epstein-Barr virus diagnostic market, but it caters mostly to pathology labs running in situ hybridization tests to spot latent infection of tumors. From 2025 to 2027, procurement for this market will be shaped by regulatory modernization, lab automation, and oncology investment. According to the most recent study by Lucintel, Country-specific execution far outweighs global demand when considering priority markets. • United States: Regulatory alignment and oncology investment. January 2025 brought the FDA’s continued support for the 510(k) and laboratory developed test, especially for EBV, while the National Cancer Institute’s FY2025 budget reached $7 billion. The continued validation of EBER assays will continue to be adopted in pathology lab networks over the next 3 years or more. • China: Investment in domestic diagnostics and hospital procurement. In March 2025, the Chinese National Medical Products Administration continued to register locally produced molecular and pathology assays, and as part of the Healthy China program, lab and hospital modernization. This will have a positive impact on local supply EBER probes and decrease market reliance on imports. • Germany: Digital pathology investment and European compliance. In February 2025, amendments to the Digital Act were put forth by the Federal Ministry of Health, as well as creating digital and diagnostic infrastructure, favoring standardized and image-linked EBER. • India: Funds allocated to the Public Health Research Program and manufacturing. In February 2025, the budget allocated ₹99,858 crore to the Health and Family Welfare Department. With the growing number of public and private pathology labs, there will be increased access to EBV testing. Additionally, domestic production of reagents will bring more consistency to the supply of EBER probes. • Japan: Precision oncology funding and laboratory automation. In April 2025, the Ministry of Health, Labour and Welfare implemented the FY2025 medical fee reform. This is expected to enhance the reimbursement of more sophisticated diagnostic services. It thereby facilitates robust reimbursement for EBER tests and automated slide readings at cancer centers. Features of the Global EBER Probe Market Market Size Estimates: eber probe market size estimation in terms of value ($M). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: eber probe market size by type, product, application, and region in terms of value ($M). Regional Analysis: eber probe market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, products, applications, and regions for the eber probe market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eber probe market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the eber probe market by type (RNA probe and DNA probe), product (dig-labeled probes, biotin-labeled probes, and direct fluorescent-labeled probes), application (hospital, clinic, research institutions, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?